NanoViricides (NYSE:NNVC) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of NanoViricides (NYSE:NNVCFree Report) from a hold rating to a sell rating in a research note issued to investors on Monday.

NanoViricides Trading Down 3.8 %

Shares of NYSE:NNVC opened at $1.28 on Monday. NanoViricides has a 12-month low of $1.00 and a 12-month high of $3.59. The business has a 50 day moving average of $1.45 and a two-hundred day moving average of $1.82. The company has a market capitalization of $17.85 million, a PE ratio of -1.68 and a beta of 0.96.

NanoViricides (NYSE:NNVCGet Free Report) last posted its earnings results on Friday, September 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01.

Institutional Trading of NanoViricides

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in shares of NanoViricides by 20.8% during the 2nd quarter. Renaissance Technologies LLC now owns 102,100 shares of the company’s stock valued at $176,000 after buying an additional 17,600 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in NanoViricides by 44.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 53,335 shares of the company’s stock worth $80,000 after acquiring an additional 16,500 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC acquired a new position in NanoViricides during the second quarter worth $26,000. 10.30% of the stock is owned by institutional investors and hedge funds.

NanoViricides Company Profile

(Get Free Report)

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.

Read More

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.